Direct Oral Anticoagulants for Pulmonary Embolism
Hämostaseologie · 01.06.2024 · 44 (03) · 206-217
DOI: 10.1055/a-2105-8736 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.06.2024. Verfasst von Roberto Pizzi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine and Thrombosis Center, Ospedale di Circolo di Varese and Department of Medicine and Surgery, University of Insubria,…. Hauptthemen laut MEDLINE: Pulmonary Embolism, Anticoagulants. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or without lead-in heparin therapy are effective alternatives with fewer adverse effects. This evidence has led to important changes in the guidelines on the treatment of VTE, including pulmonary embolism (PE), with the DOACs being now recommended as the first therapeutic choice. Additional research has contributed to identifying low-risk PE patients who can benefit from outpatient management or from early discharge from the emergency department with DOAC treatment. There is evidence to support the use of DOACs in intermediate-risk PE patients as well as in high-risk patients receiving thrombolytic treatment. The use of DOACs has also been proven to be safe and effective in special populations of PE patients, such as patients with renal impairment, liver impairment, and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine and Thrombosis Center, Ospedale di Circolo di Varese and Department of Medicine and Surgery, University of Insubria, Varese, Italy.
- Vascular and Internal Medicine- Stroke Unit, University of Perugia, Perugia, Italy.
Zitieren
APA
Pizzi, R., Cimini, L. A., Ageno, W., & Becattini, C. (2024). Direct Oral Anticoagulants for Pulmonary Embolism. Hämostaseologie, 44(03), 206-217. https://doi.org/10.1055/a-2105-8736
Vancouver
Pizzi R, Cimini LA, Ageno W, Becattini C. Direct Oral Anticoagulants for Pulmonary Embolism. Hämostaseologie. 2024;44(03):206-217. doi:10.1055/a-2105-8736
BibTeX
@article{Pizzi2024,
author = {Pizzi, Roberto and Cimini, Ludovica Anna and Ageno, Walter and Becattini, Cecilia},
title = {Direct Oral Anticoagulants for Pulmonary Embolism},
journal = {Hämostaseologie},
year = {2024},
volume = {44},
number = {03},
pages = {206--217},
doi = {10.1055/a-2105-8736}
}
EUVIMED